TOB1 is regulated by EGF-dependent HER2 and EGFR signaling, is highly phosphorylated, and indicates poor prognosis in node-negative breast cancer.

Clinical and animal studies have shown that coexpression of the receptor tyrosine kinases HER2 and epidermal growth factor (EGF) receptor (EGFR) indicates a highly metastatic phenotype of breast cancer. In a cellular model of this phenotype using differential gene expression analysis, we identified TOB1 to be up-regulated depending on EGF stimulation and transduction through phosphorylation of HER2 tyrosine 1248. mRNA expression analysis of breast cancers from a cohort of node-negative patients showed significantly shortened distant metastasis-free survival for patients with high TOB1 expression. In subsequent tissue microarray studies of 725 clinical samples, high HER2 and EGF protein levels were significantly correlated with TOB1 expression in breast cancer, whereas EGFR and EGF levels correlated with TOB1 phosphorylation. We did not observe a correlation between TOB1 expression and cyclin D1, which was previously suggested to mediate the antiproliferative effect of unphosphorylated TOB1. A positive correlation of TOB1 phosphorylation status with proliferation marker Ki67 suggests that elevated TOB1 phosphorylation might abrogate the antiproliferative effect of TOB1 in breast cancer. This suggests a new regulatory role for TOB1 in cancer progression with particular significance in HER2- and/or EGFR-positive breast cancers.

[1]  P. V. van Diest,et al.  The origin of vimentin expression in invasive breast cancer: epithelial–mesenchymal transition, myoepithelial histogenesis or histogenesis from progenitor cells with bilinear differentiation potential? , 2005, The Journal of pathology.

[2]  D. Berry,et al.  c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. , 1994, The New England journal of medicine.

[3]  G. Assmann,et al.  c‐erbB‐2/EGFR as dominant heterodimerization partners determine a motogenic phenotype in human breast cancer cells , 1999, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[4]  A. Miyauchi,et al.  Phosphorylation and inactivation of Tob contributes to the progression of papillary carcinoma of the thyroid. , 2005, Cancer letters.

[5]  Toru Suzuki,et al.  Alteration of expression or phosphorylation status of tob, a novel tumor suppressor gene product, is an early event in lung cancer. , 2003, Cancer letters.

[6]  J. Farndon,et al.  EPIDERMAL-GROWTH-FACTOR RECEPTOR STATUS AS PREDICTOR OF EARLY RECURRENCE OF AND DEATH FROM BREAST CANCER , 1987, The Lancet.

[7]  J. Nesland,et al.  EGFR family expression in breast carcinomas. c‐erbB‐2 and c‐erbB‐4 receptors have different effects on survival , 2002, The Journal of pathology.

[8]  Toru Suzuki,et al.  Phosphorylation of three regulatory serines of Tob by Erk1 and Erk2 is required for Ras-mediated cell proliferation and transformation. , 2002, Genes & development.

[9]  S. Eccles,et al.  Cell biology of lymphatic metastasis. The potential role of c-erbB oncogene signalling. , 2000, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

[10]  G. Sauter,et al.  Expression of early placenta insulin-like growth factor in breast cancer cells provides an autocrine loop that predominantly enhances invasiveness and motility. , 2005, Endocrine-related cancer.

[11]  N. Hynes,et al.  ErbB‐2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling , 1997, The EMBO journal.

[12]  S. Eccles.  The Role of c-erbB-2/HER2/neu in Breast Cancer Progression and Metastasis , 2001, Journal of Mammary Gland Biology and Neoplasia.

[13]  N. Hynes,et al.  Single-chain antibody-mediated intracellular retention of ErbB-2 impairs Neu differentiation factor and epidermal growth factor signaling , 1995, Molecular and cellular biology.

[14]  J. Foekens,et al.  Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer , 2005, The Lancet.

[15]  Amanda Y. Chan,et al.  EGF stimulates lamellipod extension in metastatic mammary adenocarcinoma cells by an actin-dependent mechanism , 2004, Clinical & Experimental Metastasis.

[16]  M. Cronin,et al.  A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. , 2004, The New England journal of medicine.

[17]  E. Nishida,et al.  Identification of the Anti-proliferative Protein Tob as a MAPK Substrate* , 2002, The Journal of Biological Chemistry.

[18]  Naoto Hirano,et al.  Tob is a negative regulator of activation that is expressed in anergic and quiescent T cells , 2001, Nature Immunology.

[19]  M. Toi,et al.  Role of epidermal growth factor receptor expression in primary breast cancer: results of a biochemical study and an immunocytochemical study , 2004, Breast Cancer Research and Treatment.

[20]  C. Jackisch,et al.  Selection of potentially metastatic subpopulations expressing c-erbB-2 from breast cancer tissue by use of an extravasation model. , 1998, The American journal of pathology.

[21]  C. Osborne,et al.  HER-2 Amplification, HER-1 Expression, and Tamoxifen Response in Estrogen Receptor-Positive Metastatic Breast Cancer , 2004, Clinical Cancer Research.

[22]  A. Ruíz,et al.  Prognostic significance of c-erbB-2/neu amplification and epidermal growth factor receptor (EGFR) in primary breast cancer and their relation to estradiol receptor (ER) status. , 1997, Clinica chimica acta; international journal of clinical chemistry.

[23]  R. Tibshirani,et al.  Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[24]  S. Tsutsui,et al.  Prognostic value of the combination of epidermal growth factor receptor and c-erbB-2 in breast cancer. , 2003, Surgery.

[25]  Y. Nakamura,et al.  Tob, a novel protein that interacts with p185erbB2, is associated with anti-proliferative activity. , 1996, Oncogene.

[26]  Jan Mous,et al.  Touching base , 2000, Nature Genetics.

[27]  W. Muller,et al.  The role of the epidermal growth factor receptor family in mammary tumorigenesis and metastasis. , 1999, Experimental cell research.

[28]  A. Wells,et al.  Epidermal growth factor modulates cell attachment to hyaluronic acid by the cell surface glycoprotein CD44 , 1996, Clinical & Experimental Metastasis.

[29]  M. Greene,et al.  Structural analysis of p185c-neu and epidermal growth factor receptor tyrosine kinases: oligomerization of kinase domains. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[30]  B. Gusterson,et al.  Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  T. Noda,et al.  Mice lacking a transcriptional corepressor Tob are predisposed to cancer. , 2003, Genes & development.

[32]  Thomas Dittmar,et al.  Induction of cancer cell migration by epidermal growth factor is initiated by specific phosphorylation of tyrosine 1248 of c‐erbB‐2 receptor via epidermal growth factor receptor , 2002, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[33]  M. Kraus,et al.  Overexpression of erbB-2 or EGF receptor proteins present in early stage mammary carcinoma is detected simultaneously in matched primary tumors and regional metastases. , 1989, Oncogene.

[34]  W. Dougall,et al.  Heterodimerization of epidermal growth factor receptor and wild-type or kinase-deficient Neu: a mechanism of interreceptor kinase activation and transphosphorylation. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[35]  Suo,et al.  Type 1 protein tyrosine kinases in benign and malignant breast lesions , 1998, Histopathology.

[36]  Aaron P. Campbell,et al.  Suppression subtractive hybridization: a method for generating differentially regulated or tissue-specific cDNA probes and libraries. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[37]  J. Kononen,et al.  Tissue microarrays for high-throughput molecular profiling of tumor specimens , 1998, Nature Medicine.

[38]  S. Hirohashi,et al.  Dominant negative inhibition of the association between beta-catenin and c-erbB-2 by N-terminally deleted beta-catenin suppresses the invasion and metastasis of cancer cells. , 1996, Oncogene.

[39]  W. E. Gye,et al.  CANCER RESEARCH , 1923, British medical journal.

[40]  Toru Suzuki,et al.  Nuclear localization of Tob is important for regulation of its antiproliferative activity , 2004, Oncogene.

[41]  J. R. Reeves,et al.  Outcome and human epidermal growth factor receptor (HER) 1–4 status in invasive breast carcinomas with proliferation indices evaluated by bromodeoxyuridine labelling , 2004, Breast Cancer Research.

[42]  K. Fujikawa,et al.  The Ets‐1 and Ets‐2 transcription factors activate the promoters for invasion‐associated urokinase and collagenase genes in response to epidermal growth factor , 1998, International journal of cancer.

[43]  M. Noda,et al.  Enhancing Effect of Tob Deficiency on Bone Formation Is Specific to Bone Morphogenetic Protein‐Induced Osteogenesis , 2002, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[44]  H Buerger,et al.  Tissue microarrays: a new approach for quality control in immunohistochemistry , 2002, Journal of clinical pathology.

[45]  H. P. Fell,et al.  The Relationship between Human Epidermal Growth-like Factor Receptor Expression and Cellular Transformation in NIH3T3 Cells* , 1996, The Journal of Biological Chemistry.

[46]  D. Kwiatkowski,et al.  Gelsolin as a negative prognostic factor and effector of motility in erbB-2-positive epidermal growth factor receptor-positive breast cancers. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[47]  J. Feldner,et al.  Cancer cell motility--on the road from c-erbB-2 receptor steered signaling to actin reorganization. , 2002, Experimental cell research.

[48]  G. Giacco,et al.  Prognosis in node-negative breast cancer , 2005, Breast Cancer Research and Treatment.